Skip to main content
Top
Published in: Clinical and Translational Oncology 10/2012

01-10-2012 | Research Article

Induced apoptosis in human prostate cancer cells by blocking of vascular endothelial growth factor by siRNA

Authors: A. Deezagi, S. Ansari-Majd, N. Vaseli-Hagh

Published in: Clinical and Translational Oncology | Issue 10/2012

Login to get access

Abstract

Introduction

Vascular endothelial growth factor (VEGF) regulates several cell functions including; proliferation, differentiation, permeability, vascular tone, and the production of vasoactive molecules. The purpose of this study was to evaluate the potency of specific short-interfering RNA (siRNA) to suppress human VEGF expression by siRNA and investigate the effects of VEGF down-regulation on the cell proliferation and apoptosis of the human prostate cancer cell lines DU-145.

Methods

Transfection was performed using X-tremeGENE siRNA transfection reagent. At different time intervals, transfected cells were harvested and total RNA was extracted for RT-PCR. The VEGF content in supernatants were measured by ELISA. Inhibition of cell growth by hVEGF-siRNA was measured by using cell proliferation ELISA BrdU assay. Apoptotic cells were evaluated by using annexin-V-FITC apoptotic detection method.

Results

Transfection of hVEGF-siRNA resulted in statistically significant inhibition of hVEGF-mRNA that in turn caused a marked reduction in the expression of hVEGF. The cell growth was assessed every 24 h for 4 days after siRNA treatment resulted in a marked inhibition of cell proliferation as compared to scramble siRNA. The results of apoptosis showed that approximately 15 % of the cells treated with control-siRNA manifested evident apoptotic changes after 24 hpt, whereas DU-145 cells treated with hVEGF-siRNA significantly were positive, that is to say, 53 % at 72 hpt 23.9 ± 2.78 % (P < 0.001) and 13 ± 1.57 % at 96 hpt.

Conclusion

Our findings indicate that siRNA are effective in eliciting the RNAi pathway in cancerous cells and that specific siRNA efficiently down-regulate VEGF expression. They could decrease VEGF production and induce apoptosis, which may also be linked to the inhibition of cancerous cell proliferation. Therefore, it can be concluded that siRNA-mediated suppression of VEGF represents a powerful tool against prostate cancer cell proliferation. VEGF down-regulation exerts a direct anti-apoptotic function in the DU-145 cell lines and promises the development of drugs for cancer therapy.
Literature
1.
go back to reference Napoleone F (2009) VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw 20(4):158–163 Napoleone F (2009) VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw 20(4):158–163
2.
go back to reference Nagy JA, Benjamin L, Zeng H, Dvorak AM, Dvorak HF (2008) Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis 11:109–119PubMedCrossRef Nagy JA, Benjamin L, Zeng H, Dvorak AM, Dvorak HF (2008) Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis 11:109–119PubMedCrossRef
3.
go back to reference Shibuya M, Claesson-Welsh L (2005) Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 312:549–560PubMedCrossRef Shibuya M, Claesson-Welsh L (2005) Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 312:549–560PubMedCrossRef
4.
go back to reference Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581–611PubMedCrossRef Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581–611PubMedCrossRef
5.
go back to reference Ce′be-Suarez S, Zehnder-Fja¨llman AH, Ballmer-Hofer K (2006) The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci 63:601–615CrossRef Ce′be-Suarez S, Zehnder-Fja¨llman AH, Ballmer-Hofer K (2006) The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci 63:601–615CrossRef
6.
7.
go back to reference VanCleave TT, Moore JH, Benford ML, Brock GN, Kalbfleisch T, Baumgartner RN, Lillard JW Jr, Kittles RA, Kidd LC (2010) Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk. Prostate 70(4):341–352PubMed VanCleave TT, Moore JH, Benford ML, Brock GN, Kalbfleisch T, Baumgartner RN, Lillard JW Jr, Kittles RA, Kidd LC (2010) Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk. Prostate 70(4):341–352PubMed
8.
go back to reference Delongchamps NB, Peyromaure M (2007) The role of vascular endothelial growth factor in kidney and prostate cancer. Can J Urol 14(5):3669–3677PubMed Delongchamps NB, Peyromaure M (2007) The role of vascular endothelial growth factor in kidney and prostate cancer. Can J Urol 14(5):3669–3677PubMed
9.
go back to reference Duque JL, Loughlin KR, Adam RM, Kantoff P, Mazzucchi E, Freeman (2006) Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen. Clinics (Sao Paulo) 61(5):401–408CrossRef Duque JL, Loughlin KR, Adam RM, Kantoff P, Mazzucchi E, Freeman (2006) Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen. Clinics (Sao Paulo) 61(5):401–408CrossRef
10.
go back to reference Margaritescu CL, Pirici D, Simionescu C, Mogoanta L, Raica M, Stinga A, Ciurea R, Stepan A, Stinga A, Ribatti D (2009) VEGF and VEGFRs expression in oral squamous cell carcinoma, Romanian. J Morphol Embryol 50(4):527–548 Margaritescu CL, Pirici D, Simionescu C, Mogoanta L, Raica M, Stinga A, Ciurea R, Stepan A, Stinga A, Ribatti D (2009) VEGF and VEGFRs expression in oral squamous cell carcinoma, Romanian. J Morphol Embryol 50(4):527–548
11.
go back to reference Gasparini G, Longo R, Toi M, Ferrara N (2005) Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol 2:562–577PubMedCrossRef Gasparini G, Longo R, Toi M, Ferrara N (2005) Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol 2:562–577PubMedCrossRef
12.
go back to reference Presta LG, Chen H, O’Connor SJ et al (1997) Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593–4599PubMed Presta LG, Chen H, O’Connor SJ et al (1997) Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593–4599PubMed
13.
go back to reference Manley PW, Martiny-Baron G, Schlaeppi JM, Wood JM (2002) Therapies directed at vascular endothelial growth factor. Expert Opin Investig Drugs 11:1715–1736PubMedCrossRef Manley PW, Martiny-Baron G, Schlaeppi JM, Wood JM (2002) Therapies directed at vascular endothelial growth factor. Expert Opin Investig Drugs 11:1715–1736PubMedCrossRef
14.
go back to reference Holash J, Davis S, Papadopoulos N et al (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99:11393–11398PubMedCrossRef Holash J, Davis S, Papadopoulos N et al (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99:11393–11398PubMedCrossRef
15.
go back to reference Fumitaka T, Takahiro O (2006) Therapeutic potential of RNA interference against cancer. Cancer Sci 97(8):689–696CrossRef Fumitaka T, Takahiro O (2006) Therapeutic potential of RNA interference against cancer. Cancer Sci 97(8):689–696CrossRef
17.
go back to reference Hammond SM, Caudy AA, Hannon GJ (2001) Post-transcriptional gene silencing by double-stranded RNA. Nat Rev Genet 2:110PubMedCrossRef Hammond SM, Caudy AA, Hannon GJ (2001) Post-transcriptional gene silencing by double-stranded RNA. Nat Rev Genet 2:110PubMedCrossRef
18.
go back to reference Parra E, Ortega A, Saenz L (2009) Down-regulation of Egr-1 by siRNA inhibits growth of human prostate carcinoma cell line PC-3. Oncol Rep 22(6):1513–1518PubMed Parra E, Ortega A, Saenz L (2009) Down-regulation of Egr-1 by siRNA inhibits growth of human prostate carcinoma cell line PC-3. Oncol Rep 22(6):1513–1518PubMed
19.
go back to reference Oh BY, Lee RA, Kim KH (2011) siRNA targeting Livin decreases tumor in a xenograft model for colon cancer. World J Gastroenterol 17(20):2563–2571PubMedCrossRef Oh BY, Lee RA, Kim KH (2011) siRNA targeting Livin decreases tumor in a xenograft model for colon cancer. World J Gastroenterol 17(20):2563–2571PubMedCrossRef
20.
go back to reference Ning S, Fuessel S, Kotzsch M, Kraemer K, Kappler M, Schmidt U, Taubert H, Wirth MP, Meye A (2004) siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth. Int J Oncol 25:1065PubMed Ning S, Fuessel S, Kotzsch M, Kraemer K, Kappler M, Schmidt U, Taubert H, Wirth MP, Meye A (2004) siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth. Int J Oncol 25:1065PubMed
21.
go back to reference Wu W, Yao D, Wang Y, Qiu L, Sai W, Yang J, Yao N, Li S, Bian Y, Wang Z, Yao D (2010) Suppression of human hepatoma (HepG2) cell growth by nuclear factor-kappaB/p65 specific siRNA. Tumour Biol 31(6):605–611PubMedCrossRef Wu W, Yao D, Wang Y, Qiu L, Sai W, Yang J, Yao N, Li S, Bian Y, Wang Z, Yao D (2010) Suppression of human hepatoma (HepG2) cell growth by nuclear factor-kappaB/p65 specific siRNA. Tumour Biol 31(6):605–611PubMedCrossRef
22.
go back to reference Miri-Moghaddam E, Deezagi A, Soheili ZS, Shariati P (2010) Apoptosis and reduced cell proliferation of HL-60 cell line caused by human telomerase reverse transcriptase inhibition by siRNA. Acta Haematol 124(2):72–78PubMedCrossRef Miri-Moghaddam E, Deezagi A, Soheili ZS, Shariati P (2010) Apoptosis and reduced cell proliferation of HL-60 cell line caused by human telomerase reverse transcriptase inhibition by siRNA. Acta Haematol 124(2):72–78PubMedCrossRef
23.
go back to reference Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A (2004) Rational siRNA design for RNA interference. Nat Biotechnol 22:326 Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A (2004) Rational siRNA design for RNA interference. Nat Biotechnol 22:326
24.
go back to reference Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402 Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402
25.
go back to reference Wang Q, Liu M, Kozasa T, Rothestein JD, Sternweis PC, Neubig RR (2004) Ribozyme and siRNA-mediated suppression of RGS containing RhoGEF proteins. Methods Enzymol 389:244–265PubMedCrossRef Wang Q, Liu M, Kozasa T, Rothestein JD, Sternweis PC, Neubig RR (2004) Ribozyme and siRNA-mediated suppression of RGS containing RhoGEF proteins. Methods Enzymol 389:244–265PubMedCrossRef
26.
go back to reference Lu PY, Xie FY, Woodle MC (2003) siRNA-mediated antitumorigenesis for drug target validation and therapeutics. Curr Opin Mol Ther 5:225 Lu PY, Xie FY, Woodle MC (2003) siRNA-mediated antitumorigenesis for drug target validation and therapeutics. Curr Opin Mol Ther 5:225
27.
go back to reference Hoeijmakers JHJ (2001) Genome maintenance mechanisms for preventing cancer. Nature 411:366 Hoeijmakers JHJ (2001) Genome maintenance mechanisms for preventing cancer. Nature 411:366
28.
go back to reference Woessner RD, Wright PS, Loudy DE, Wallace CD, Montgomery LR (1998) Micro-autoradiographic quantitation of vascular endothelial growth factor mRNA level in human prostate specimens containing normal and neoplastic epithelium. Exp Mol Pathol 65(1):37–52PubMedCrossRef Woessner RD, Wright PS, Loudy DE, Wallace CD, Montgomery LR (1998) Micro-autoradiographic quantitation of vascular endothelial growth factor mRNA level in human prostate specimens containing normal and neoplastic epithelium. Exp Mol Pathol 65(1):37–52PubMedCrossRef
29.
go back to reference Gerber HP, Hillan KJ, Ryan AM et al (1999) VEGF is required for growth and survival in neonatal mice. Development 126:1149–1159PubMed Gerber HP, Hillan KJ, Ryan AM et al (1999) VEGF is required for growth and survival in neonatal mice. Development 126:1149–1159PubMed
30.
go back to reference Korsisaari N, Kasman IM, Forrest WF et al (2007) Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice. Proc Natl Acad Sci USA 104:10625–10630PubMedCrossRef Korsisaari N, Kasman IM, Forrest WF et al (2007) Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice. Proc Natl Acad Sci USA 104:10625–10630PubMedCrossRef
31.
go back to reference Korsisaari N, Ross J, Wu X et al (2008) Blocking vascular endothelial growth factor-a inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1. Clin Cancer Res 14:249–258PubMedCrossRef Korsisaari N, Ross J, Wu X et al (2008) Blocking vascular endothelial growth factor-a inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1. Clin Cancer Res 14:249–258PubMedCrossRef
32.
go back to reference Murukesh N, Dive C, Jayson GC (2010) Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. British J Cancer 102:8–18CrossRef Murukesh N, Dive C, Jayson GC (2010) Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. British J Cancer 102:8–18CrossRef
33.
go back to reference Yin Y, Cao LY, Wu WQ, Li H, Jiang Y, Zhang HF (2010) Blocking effects of siRNA on VEGF expression in human colorectal cancer cells. World J Gastroenterol 16(9):1086–1092PubMedCrossRef Yin Y, Cao LY, Wu WQ, Li H, Jiang Y, Zhang HF (2010) Blocking effects of siRNA on VEGF expression in human colorectal cancer cells. World J Gastroenterol 16(9):1086–1092PubMedCrossRef
34.
go back to reference Raskopf E, Vogt A, Sauerbruch T, Schmitz V (2008) siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo. J Hepatol 49(6):977–984PubMedCrossRef Raskopf E, Vogt A, Sauerbruch T, Schmitz V (2008) siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo. J Hepatol 49(6):977–984PubMedCrossRef
35.
go back to reference Salva E, Akbuğa J (2010) In vitro silencing effect of chitosan nanoplexes containing siRNA expressing vector targeting VEGF in breast cancer cell lines. Pharmazie 65(12):896–902PubMed Salva E, Akbuğa J (2010) In vitro silencing effect of chitosan nanoplexes containing siRNA expressing vector targeting VEGF in breast cancer cell lines. Pharmazie 65(12):896–902PubMed
36.
go back to reference Mei J, Gao Y, Zhang L, Cai X, Qian Z, Huang H, Huang W (2008) VEGF-siRNA silencing induces apoptosis, inhibits proliferation and suppresses vasculogenic mimicry in osteosarcoma in vitro. Exp Oncol 30(1):29–34PubMed Mei J, Gao Y, Zhang L, Cai X, Qian Z, Huang H, Huang W (2008) VEGF-siRNA silencing induces apoptosis, inhibits proliferation and suppresses vasculogenic mimicry in osteosarcoma in vitro. Exp Oncol 30(1):29–34PubMed
37.
go back to reference Ferrer FA, Miller LJ, Lindquist R, Kowalczyk P, Laudone VP, Albertsen PC, Kreutzer DL (1999) Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 54:567–572PubMedCrossRef Ferrer FA, Miller LJ, Lindquist R, Kowalczyk P, Laudone VP, Albertsen PC, Kreutzer DL (1999) Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 54:567–572PubMedCrossRef
38.
go back to reference Bellezza I, Bracarda S, Caserta C, Minelli A (2006) Targeting of EGFR tyrosine kinase by ZD1839 (“Iressa”) in androgen-responsive prostate cancer in vitro. Mol Genet Metab 88:114–122PubMedCrossRef Bellezza I, Bracarda S, Caserta C, Minelli A (2006) Targeting of EGFR tyrosine kinase by ZD1839 (“Iressa”) in androgen-responsive prostate cancer in vitro. Mol Genet Metab 88:114–122PubMedCrossRef
39.
go back to reference Ozen M, Giri D, Ropiquet F, Mansukhani A, Ittmann M (2001) Role of fibroblast growth factor receptor signaling in prostate cancer cell survival. J Natl Cancer Inst 93:1783–1790PubMedCrossRef Ozen M, Giri D, Ropiquet F, Mansukhani A, Ittmann M (2001) Role of fibroblast growth factor receptor signaling in prostate cancer cell survival. J Natl Cancer Inst 93:1783–1790PubMedCrossRef
40.
go back to reference Gennigens C, Menetrier-Caux C, Droz JP (2006) Insulin-like growth factor (IGF) family and prostate cancer. Crit Rev Oncol Hematol 58:124–145PubMedCrossRef Gennigens C, Menetrier-Caux C, Droz JP (2006) Insulin-like growth factor (IGF) family and prostate cancer. Crit Rev Oncol Hematol 58:124–145PubMedCrossRef
41.
go back to reference Kisielewska J, Ligeza J, Klein A (2008) The effect of tyrosine kinase inhibitors, tyrphostins: AG1024 and SU1498, on autocrine growth of prostate cancer cells (DU145). Folia Histochem Cytobiol 46:185–191PubMedCrossRef Kisielewska J, Ligeza J, Klein A (2008) The effect of tyrosine kinase inhibitors, tyrphostins: AG1024 and SU1498, on autocrine growth of prostate cancer cells (DU145). Folia Histochem Cytobiol 46:185–191PubMedCrossRef
42.
go back to reference Ligęza Janusz, Ligęza Joanna, Klein Andrzej (2011) Growth factor/growth factor receptor loops in autocrine growth regulation of human prostate cancer DU145 cells. Acta Biochim Pol 58(3):391–396PubMed Ligęza Janusz, Ligęza Joanna, Klein Andrzej (2011) Growth factor/growth factor receptor loops in autocrine growth regulation of human prostate cancer DU145 cells. Acta Biochim Pol 58(3):391–396PubMed
Metadata
Title
Induced apoptosis in human prostate cancer cells by blocking of vascular endothelial growth factor by siRNA
Authors
A. Deezagi
S. Ansari-Majd
N. Vaseli-Hagh
Publication date
01-10-2012
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 10/2012
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0868-1

Other articles of this Issue 10/2012

Clinical and Translational Oncology 10/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine